Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw an 11.85% increase on Wednesday, reaching $4.91 per share. Jim Cramer recommended buying the stock on Mad Money, emphasizing its potential with backing from Nvidia and advancements in artificial intelligence for drug approvals.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing